European Cross-Border B2C E-Commerce Report 2015
Feb 08, 2016 12:19 pm UTC| Business
Dublin, Feb. 08, 2016 -- Research and Markets (http://www.researchandmarkets.com/research/87whq3/europe) has announced the addition of the "Europe Cross-Border B2C E-Commerce 2015" report to their...
Global 2016 Report: Stem Cell Research Products, Opportunities, Tools, & Technologies
Feb 08, 2016 12:17 pm UTC| Business
Dublin, Feb. 08, 2016 -- Research and Markets (http://www.researchandmarkets.com/research/5tdqlk/stem_cell) has announced the addition of the "Stem Cell Research Products - Opportunities, Tools, ...
Global 2016 Report: Stem Cell Research Products, Opportunities, Tools, & Technologies
Feb 08, 2016 12:11 pm UTC| Business
Dublin, Feb. 08, 2016 -- Research and Markets (http://www.researchandmarkets.com/research/5tdqlk/stem_cell) has announced the addition of the "Stem Cell Research Products - Opportunities, Tools, ...
Galena Biopharma Announces Notice of Allowance of U.S. Patent for NeuVax™ (nelipepimut-S)
Feb 08, 2016 12:05 pm UTC| Business
SAN RAMON, Calif., Feb. 08, 2016 -- Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company committed to the development and commercialization of targeted oncology therapeutics that address major unmet medical...
Feb 08, 2016 12:05 pm UTC| Business
- First Dosing of Patients Expected in 1Q 2016 - - Topline Data From Phase 2a Clinical Trial With MAT2203 for the Treatment of Refractory Mucocutaneous Candidiasis Expected in 2016 - BEDMINSTER, N.J., Feb. 08, 2016 ...
Network Access Control Market Worth $4.39 Billion By 2022: Grand View Research, Inc.
Feb 08, 2016 12:04 pm UTC| Business
San Francisco, California, Feb. 08, 2016 -- The global NAC market size is expected to reach USD 4.39 billion by 2022, according to a new report by Grand View Research, Inc. Technological proliferation and demand for...
Anavex Reports Fiscal First Quarter 2016 Financial Results
Feb 08, 2016 12:00 pm UTC| Business
NEW YORK, Feb. 08, 2016 -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative...